Announcements Trials
Browse Landscape

Phase

Phase 2 28Phase 1/2 4Phase 1 4Phase EARLY_PHASE1 2Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Skin Neoplasms 1Prostatic Neoplasms 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 7Cyclophosphamide 5Metformin 4durvalumab 3Vincristine 3Radiation 3Imiquimod 3Fluorouracil 3antitumor A 2Testosterone 2Surveys and Questionnaires 2Rituximab 2Prednisone 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Lapatinib 2Immunoglobulin G 2HhAntag691 2Doxorubicin 2Disulfides 2Cisplatin 2Biopsy 2xentuzumab 1tremelimumab 1ribociclib 1posaconazole 1pexidartinib 1perflutren 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Has results × HhAntag691 × Clear all
NCT02115828 2018-07-20

A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Completed
9 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT01631331 2017-12-08

Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

Stanford University

Phase EARLY_PHASE1 Completed
15 enrolled 10 charts
Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡